Skip to main content

Observational Evaluation of Atopic Dermatitis in Pediatric Patients

Active, not recruiting · NCT03687359

Conditions: Dermatitis Atopic

At a glance

Research payments reported, 2025
$226,115
U.S. investigators named
19
Sites paid
18
Planned or actual enrollment
1,860

About the trial

Sponsor
Sanofi
Tested
Standard of care (other)
Dates
Started 2019-08-15; completion 2035-07-23
Results posted
Not yet

Primary Objectives: * To describe the characteristics of pediatric patients with moderate to severe atopic dermatitis (AD) whose disease is not adequately controlled with topical therapies or when those therapies are not medically advisable. * To evaluate the time-course of AD and selected atopic comorbidities. Secondary Objectives: * To characterize disease burden and unmet need. * To describe real-world treatment patterns (eg, dosing regimens, treatment duration, and reasons for discontinuation and/or switching). * To document the real-world effectiveness and safety of treatments.

From ClinicalTrials.gov, last updated 2025-08-15. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Sanofi US Services Inc. reported $226,115 in research payments for this study in 2025 (450 payments).

Products named: Dupixent

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.